Literature DB >> 12906258

Activation of mammalian Toll-like receptors by endogenous agonists.

Geoffrey B Johnson1, Gregory J Brunn, Jeffrey L Platt.   

Abstract

Toll-like receptors activate innate and adaptive immune systems in mammals. This ancient family of receptors has been evolving since before the taxonomic split between the plant and animal kingdoms. The discovery of the mammalian Toll-like receptors was heralded as confirmation of a predicted biological system explicitly designed to detect exogenous molecules from micro-organisms. However, there is accumulating evidence that Toll-like receptors also detect endogenous agonists, such as the degradation products of macromolecules, products of proteolytic cascades, intracellular components of ruptured cells, and products of genes that are activated by inflammation. Here we review endogenous models of Toll-like receptor activation, a subject of extensive debate. Endogenous activation of mammalian Toll-like receptors may provide key insights for the treatment of multiple conditions, from atherosclerosis to transplant rejection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906258     DOI: 10.1615/critrevimmunol.v23.i12.20

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  45 in total

1.  Expression of Toll-like receptors in human endometrial epithelial cells and cell lines.

Authors:  Steven L Young; Terri D Lyddon; Rebecca L Jorgenson; Michael L Misfeldt
Journal:  Am J Reprod Immunol       Date:  2004-07       Impact factor: 3.886

2.  IL-10 deficiency exacerbates the brain inflammatory response to permanent ischemia without preventing resolution of the lesion.

Authors:  Isabel Pérez-de Puig; Francesc Miró; Angélica Salas-Perdomo; Ester Bonfill-Teixidor; Maura Ferrer-Ferrer; Leonardo Márquez-Kisinousky; Anna M Planas
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-11       Impact factor: 6.200

Review 3.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

Review 4.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Authors:  P J Cimino; C Dirk Keene; Richard M Breyer; Kathleen S Montine; Thomas J Montine
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

5.  Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction.

Authors:  Justin Pollara; R Whitney Edwards; Liwen Lin; Victoria A Bendersky; Todd V Brennan
Journal:  JCI Insight       Date:  2018-08-09

6.  Effects of Toll-Like Receptor 4 Antagonists Against Cerebral Vasospasm After Experimental Subarachnoid Hemorrhage in Mice.

Authors:  Fumihiro Kawakita; Masashi Fujimoto; Lei Liu; Fumi Nakano; Yoshinari Nakatsuka; Hidenori Suzuki
Journal:  Mol Neurobiol       Date:  2016-10-13       Impact factor: 5.590

7.  Microglial CD14 activated by iNOS contributes to neuroinflammation in cerebral ischemia.

Authors:  Mian Zhou; Christie M Wang; Weng-Lang Yang; Ping Wang
Journal:  Brain Res       Date:  2013-02-14       Impact factor: 3.252

8.  Activation of TLR4-mediated NFkappaB signaling in hemorrhagic brain in rats.

Authors:  Weiyu Teng; Lishu Wang; Weishuang Xue; Chao Guan
Journal:  Mediators Inflamm       Date:  2010-01-31       Impact factor: 4.711

Review 9.  Pattern recognition via the toll-like receptor system in the human female genital tract.

Authors:  Kaei Nasu; Hisashi Narahara
Journal:  Mediators Inflamm       Date:  2010-04-11       Impact factor: 4.711

10.  The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury.

Authors:  Jaklien C Leemans; Loes M Butter; Wilco P C Pulskens; Gwendoline J D Teske; Nike Claessen; Tom van der Poll; Sandrine Florquin
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.